CryoNize™ is indicated, for medical professional use only, in the treatment of Verruca Vulgaris, Verruca Plantaris, Condylomà Acuminata, Verruca Plana, Molluscum Contagiosum, Skin Tags, Seborrhoeic Keratosis, Actinic Keratosis, and Lentigo.

Device Description

CryoNize™ is a cryosurgical system used for the treatment of Verruca Vulgaris, Verruca Plantaris, Condyloma Acuminata, Verruca Plana, Molluscum Contagiosum, Skin Tags, Seborrhoeic Keratosis, Actinic Keratosis, and Lentigo. It consists of: An aerosol canister filled with a liquid mixture of compressed gases. This mixture, or o cryogen, is composed of 95% dimethyl ether, 2% propane, and 3% isobutane (118 ml). Customized applicators ০ CryoNize™ Foam Tip Applicators-two different shapes/sizes . CryoNize™ Zone Applicators—six different sizes (3mm, 5mm, 7mm, 12mm, 15mm) . Instructions for Use Booklet O Quick Guide for Use o o Carrying Case Practice Mouse Pad o

AI/ML Overview

The provided text describes the CryoNize™ device, a cryosurgical system for various dermatological lesions, and its premarket notification (K103310). However, it does not contain information about specific acceptance criteria or a study that proves the device meets those criteria.

Instead, the submission focuses on establishing substantial equivalence to previously cleared predicate devices (Histofreezer® and Verruca-Freeze™ Cryosurgery Delivery System) based on technological characteristics and intended use.

Here's a breakdown of why the requested information is largely absent:

A table of acceptance criteria and the reported device performance: This information is not provided. The document states, "To date, no performance standards have been finalized which affect this device." This indicates that the device was not evaluated against predefined performance criteria.
Sample size used for the test set and the data provenance (e.g. country of origin of the data, retrospective or prospective): No test set, clinical study, or performance data is mentioned.
Number of experts used to establish the ground truth for the test set and the qualifications of those experts (e.g. radiologist with 10 years of experience): Not applicable, as no ground truth establishment for a test set is described.
Adjudication method (e.g. 2+1, 3+1, none) for the test set: Not applicable, as no test set requiring adjudication is described.
If a multi reader multi case (MRMC) comparative effectiveness study was done, If so, what was the effect size of how much human readers improve with AI vs without AI assistance: Not applicable. The CryoNize™ is a physical cryosurgical device, not an AI-powered diagnostic or assistive tool, so an MRMC study related to AI assistance would not be relevant.
If a standalone (i.e. algorithm only without human-in-the-loop performance) was done: Not applicable, as it's a physical device, not an algorithm.
The type of ground truth used (expert consensus, pathology, outcomes data, etc): Not applicable, as no performance study or ground truth establishment is described. The approval is based on substantial equivalence to predicate devices, implying that their established safety and effectiveness implicitly serve as the "ground truth" for the new device's suitability.
The sample size for the training set: Not applicable, as no algorithm or training set is involved.
How the ground truth for the training set was established: Not applicable.

In summary: The K103310 submission for CryoNize™ is a substantial equivalence determination, not a performance study. It relies on demonstrating that the new device is as safe and effective as existing legally marketed predicate devices by comparing its technological characteristics and intended use, rather than presenting new clinical or performance data against specific acceptance criteria.

Summary

{0}------------------------------------------------

FEB - 9 2011

PREMARKET NOTIFICATION Traditional 510(K) SUMMARY

K103310

Submitter's Name:	3JT Enterprises, LLC., dba CryoNize
Address:	2000 N. Racine Ave., Suite 3100, Chicago, IL 60614
Telephone Number:	(312)-952-5462
Fax Number:	866-379-5579
Contact Person:	Anthony K. Goldboss, M.D.
Date Prepared:	November 7th, 2010

Device Name:

Proprietary Name:	CryoNize™
Usual Name:	CryoNize™

Devices to Which Substantial Equivalence is Claimed:

Histofreezer® Device, by OraSure Technologies, Inc. (Primary Predicate including general labeling and flammability label) -- K023487, K990877, K971392, K93327, K931299, K924114, K911420, K982358.

Verruca-Freeze Cryosurgery Delivery System™, by CryoSurgery, Inc. (Secondary Predicate including labeling) - K982506, K955083, K944221, K881349.

Device Classification:

CryoNize™ is a cryogenic device classified under 21 CFR 878.4350 as a Class II medical device. The general and plastic surgery panel cryogenic classification name for a cryosurgical unit and accessories is product code GEH.

Description of Device:

{1}------------------------------------------------

lt consists of:

An aerosol canister filled with a liquid mixture of compressed gases. This mixture, or o cryogen, is composed of 95% dimethyl ether, 2% propane, and 3% isobutane (118 ml).
Customized applicators ০
- CryoNize™ Foam Tip Applicators-two different shapes/sizes .
- CryoNize™ Zone Applicators—six different sizes (3mm, 5mm, 7mm, 12mm, 15mm) .
Instructions for Use Booklet O
Quick Guide for Use o
o Carrying Case
Practice Mouse Pad o

Performance Standards:

To date, no performance standards have been finalized which affect this device.

Intended Use Statement:

Comparision of Technological Characteristics:

CryoNize™ is for the treatment of Verruca Vulgaris, Verruca Plantaris, Condyloma Acuminata, Verruca Plana, Molluscum Contagiosum, Skin Tags, Seborrhoeic Keratosis, Actinic Keratosis, and Lentigo. It is substantially equivalent to the Histofreezer® Device (K023487) and the Verruca-Freeze™ Cryosurgery Delivery System (K982506).

All three devices are portable aerosol cryosurgical systems that contain a canister filled with cryogen and foam tip applicators. When the cryogen is dispensed, it saturates the foam tip. The foam tip is then applied directly to the desired area of treatment. Subsequently, this freezes the skin lesion. These devices are substantially equivalent.

CryoNize™ has a second type of applicator which can be used, like Verruca-Freeze™ Cryosurgery Delivery System. CryoNize™ Zone Applicators are substantially equivalent to Verruca-Freeze™ Cryosurgery Delivery System Limiting Cones.

{2}------------------------------------------------

Labeling:

The labeling of CryoNize™ has been prepared to ensure the medical professional has adequate and clear instructions for safety and usage. It includes carrying case and canister labeling, Instructions for Use Booklet, and a Quick Guide for Use. The labeling, safety and warning statements are substantially equivalent to the predicate devices.

Conclusion:

Based on the information presented above, it is concluded that the proposed CryoNize™ is safe and effective for its intended use and is substantially equivalent to the primary and secondary predicate devices. Also, the labeling is substantially equivalent to the predicate devices.

{3}------------------------------------------------

Image /page/3/Picture/1 description: The image shows the logo for the U.S. Department of Health & Human Services. The logo consists of a stylized eagle or bird-like figure with three curved lines representing its body and wings. The logo is surrounded by text that reads "DEPARTMENT OF HEALTH & HUMAN SERVICES - USA" in a circular arrangement.

Food and Drug Administration 10903 New Hampshire Avenue Document Control Room -WO66-G609 Silver Spring, MD 20993-0002

3JT Enterprises, LLC % Anthony K. Goldboss, M.D. 2000 North Racine Avenue, Suite 3100 Chicago, Illinois 60614

Re: K103310

FEB - 9 201

Trade/Device Name: CyroNize™ Regulation Number: 21 CFR 878.4350 Regulation Name: Cyrosurgical unit and accessories Regulatory Class: Class II Product Code: GEH Dated: January 11, 2011 Received: January 18, 2011

Dear Dr. Goldboss:

. . .

We have reviewed your Section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you; however, that device labeling must be truthful and not misleading.

If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.

Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must

{4}------------------------------------------------

Page 2 -- Anthony K. Goldboss, M.D.

comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting (reporting of medical device-related adverse events) (21 CFR 803); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820); and if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR 1000-1050.

If you desire specific advice for your device on our labeling regulation (21 CFR Part 801), please go to http://www.fda.gov/AboutFDA/CentersOffices/CDRH/CDRHOffices/ucm115809.htm for the Center for Devices and Radiological Health's (CDRH's) Office of Compliance. Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21CFR Part 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to

http://www.fda.gov/MedicalDevices/Safety/ReportaProblem/default.htm for the CDRH's Office of Surveillance and Biometrics/Division of Postmarket Surveillance.

You may obtain other general information on your responsibilities under the Act from the Division of Small Manufacturers, International and Consumer Assistance at its toll-free number (800) 638-2041 or (301) 796-7100 or at its Internet address

http://www.fda.gov/MedicalDevices/Resourcesfor You/Industry/default.htm.

Sincerely vours.

Mark N. Melkerson Director Division of Surgical. Orthopedic And Restorative Devices Office of Device Evaluation Center for Devices and Radiological Health

Enclosure

{5}------------------------------------------------

Indications for Use Form

510(k) Number (if known): K103310

CryoNize™ Device Name:

Indication for Use: CryoNize™ is indicated for use in the treatment of the following:

Verruca Vulgaris, Verruca Plantaris, Condyloma Acuminata, Verruca Plana, Molluscum Contagiosum, Skin Tags, Seborrhoeic Keratosis, Actinic Keratosis, and Lentigo.

Prescription Use X (Part 21 CFR 801 Subpart D)

AND/OR

Over-The-Counter Use (21 CFR 801 Subpart C)

(PLEASE DO NOT WRITE BELOW THIS LINE-CONTINUE ON ANOTHER PAGE OF NEEDED)

Concurrence of CDRH, Office of In Vitro Diagnostic Devices (OIVD)

Nishida for anka
Division SiunOm

(Division of Surgical, Orthopedic, and Restorative Devices

510(k) Number K/033/0

Division Sign-Off Office of In Vitro Diagnostic Device Evaluation and Safety

510(k)

Page 1 of 1

Regulation Number and Section

§ 878.4350 Cryosurgical unit and accessories.

(a)
Identification —(1)Cryosurgical unit with a liquid nitrogen cooled cryoprobe and accessories. A cryosurgical unit with a liquid nitrogen cooled cryoprobe and accessories is a device intended to destroy tissue during surgical procedures by applying extreme cold.(2)
Cryosurgical unit with a nitrous oxide cooled cryoprobe and accessories. A cryosurgical unit with a nitrous oxide cooled cryoprobe and accessories is a device intended to destroy tissue during surgical procedures, including urological applications, by applying extreme cold.(3)
Cryosurgical unit with a carbon dioxide cooled cryoprobe or a carbon dioxide dry ice applicator and accessories. A cryosurgical unit with a carbon dioxide cooled cryoprobe or a carbon dioxide dry ice applicator and accessories is a device intended to destroy tissue during surgical procedures by applying extreme cold. The device is intended to treat disease conditions such as tumors, skin cancers, acne scars, or hemangiomas (benign tumors consisting of newly formed blood vessels) and various benign or malignant gynecological conditions affecting vulvar, vaginal, or cervical tissue. The device is not intended for urological applications.(b)
Classification. Class II.